A carregar...
Telaprevir or boceprevir triple therapy in patients with chronic hepatitis C and varying severity of cirrhosis
BACKGROUND: Risks and benefits of protease inhibitor (PI) (telaprevir or boceprevir) triple therapy in hepatitis C virus (HCV)-infected patients with mildly decompensated cirrhosis, including those wait-listed for liver transplantation (LT), are incompletely known. AIM: To assess virological respons...
Na minha lista:
| Publicado no: | Aliment Pharmacol Ther |
|---|---|
| Main Authors: | , , , , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
2014
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4385588/ https://ncbi.nlm.nih.gov/pubmed/24654657 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/apt.12718 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|